I'll have to try my vibrating dog to see if that might work, but I'm sure the battery won't last for three hours and I couldn't hold it in place that long. Will have find some other hack. They never do say if muscle recovery came back which is what survivors want. So I consider this failed research since no measurements were taken on that. I would fire the mentors and senior researchers involved for that measurement failure.
With finger vibrators and this maybe I can get my finger spasticity reduced. I shouldn't have to guess and experiment on my own, that's what stroke leadership should be doing.
7-speed Secret Love Finger Fun Vibrator Vibration Massager with Sexy Dice
I'm going to get this from amazon when I'm around enough to get packages; vibration motor
I should be able to find a small vibrating motor and velcro it to my hand
“What's measured, improves.” So said management legend and author Peter F. Drucker
The latest here:
Daily vibrotactile stimulation from a wearable device exhibits equal or greater spasticity relief than botulinum toxin in stroke.
Caitlyn Seim, Bingxian Chen, Chuzhang Han, David Vacek
Arch Phys Med Rehabil. 2023 May 4 [Epub ahead of print]
OBJECTIVE
To test the feasibility and efficacy of the VibroTactile Stimulation
(VTS) Glove, a wearable device that provides vibrotactile stimulation to
the impaired limb to reduce spastic hypertonia.
DESIGN Prospective two-arm intervention study - including one group of patients who use Botulinum toxin (BTX-A) for spasticity and one group of patients who do not use BTX-A.
SETTING
Participants were recruited through rehabilitation and neurology clinics.
PARTICIPANTS Patients
with chronic stroke (N=20; mean age=54 years, mean time since
stroke=6.9 years). Patients who were previously receiving the standard
of care (BTX-A injection) were eligible to participate, and started the
intervention 12 weeks after their last injection.
INTERVENTION
Participants were instructed to use the VTS Glove for three hours daily, at home or during everyday activities, for 8 weeks.
MAIN OUTCOME MEASURES
Spasticity was assessed with the Modified Ashworth Scale and the
Modified Tardieu Scale at baseline and then at 2-week intervals for 12
weeks. Primary outcomes were the difference from baseline and at week 8
(end of VTS Glove use) and week 12 (four weeks after stopping VTS Glove
use). Patients who were receiving BTX-A were also assessed during the 12
weeks preceding the start of VTS Glove use to monitor the effect of
BTX-A on spastic hypertonia. Range of motion and participant feedback
were also studied.
RESULTS
A clinically
meaningful difference in spastic hypertonia was found during and after
daily VTS Glove use. Modified Ashworth and Modified Tardieu scores were
reduced by an average of 0.9 (p=0.0014) and 0.7 (p=0.0003),
respectively, at week 8 of daily VTS Glove use, and by 1.1 (p=0.00025)
and 0.9 (p=0.0001), respectively, one month after stopping VTS Glove
use. For participants who used BTX-A, 6 out of 11 showed greater change
in Modified Ashworth ratings during VTS Glove use (Mean=-1.8 vs.
Mean=-1.6 with BTX-A) and 8 out of 11 showed their lowest level of
symptoms during VTS Glove use (vs. BTX-A).
CONCLUSIONS
Daily
stimulation from the VTS Glove provides relief of spasticity and
hypertonia. For more than half of participants who had regularly used
BTX-A, the VTS Glove provided equal or greater symptom relief.
No comments:
Post a Comment